Related Experiment Video
Updated: Aug 15, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
[Gemfibrozil-induced myopathy]
Insights
Gemfibrozil, a lipid-lowering drug, can cause myopathy, a muscle disorder. This risk is higher in patients with chronic renal failure, highlighting the need for careful monitoring.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Hyperlipidemia and diabetes mellitus are common comorbidities.
- Chronic renal failure increases the risk of drug-induced complications.
- Gemfibrozil is a lipid-lowering agent with known potential side effects.
Abstract:
A 61-year-old woman with hyperlipidemia was treated with gemfibrozil. She also had insulin-treated diabetes mellitus and chronic renal failure and was admitted because of severe chest pain. The ST segment was depressed and creatine kinase levels were elevated. The original diagnosis was acute myocardial infarction. In the presence of increasing chest pain, the onset of limb muscle tenderness, and increasing levels of creatine kinase, the diagnosis of myopathy secondary to gemfibrozil therapy was made and the drug was discontinued. All symptoms then subsided and creatine kinase levels returned to normal. Myopathy is a well-known complication of blood lipid-lowering drugs, especially in patients with renal failure.
Related Concept Videos
Classification of Skeletal Muscle Fibers
Slow-Twitch Muscle Fibers
Slow oxidative, muscle fibers appear red due to large numbers of capillaries and high levels of...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug toxicity: Idiosyncratic Reactions

